The latest from across eye care — curated by B-Seen
The FDA favorably reviewed plans for a phase 3 trial of urcosimod, which is being investigated for the treatment of neuropathic corneal pain, according to a press release from Okyo Pharma. The feedback came during a meeting between Okyo Pharma and the FDA, paving the way for a pivotal trial in a disease that currently has no specifically approved treatments. “Neuropathic corneal pain remains one of the most challenging and underserved conditions in eye care, with patients often living with persistent pain,” Robert J. Dempsey, CEO of Okyo Pharma, told Healio. The trial, called
GIGI Studios is celebrating its 10th anniversary in 2026, marking a decade of growth for the Barcelona-based eyewear brand. Founded on a family heritage of more than 60 years in the eyewear sector, the brand has built its identity around contemporary design, craftsmanship and a fashion-led creative direction.
A 76-year-old man presented with a 3-week history of binocular vertical diplopia. He denied change in vision, pain with eye movements, headache, scalp tenderness, jaw claudication, constitutional symptoms, dysarthria, extremity numbness or tingling, facial droop, and prior similar episodes. Ocular history was notable for dry age-related macular degeneration in the right eye, neovascular AMD in the left eye and cataract extraction bilaterally. He had previously received intravitreal anti-VEGF injections at an outside institution but had been lost to follow-up for several years. Medical history
Geriatric optometry, which focuses on the unique eye health and vision requirements of older adults, is having a moment in the vision care sector. Within this eyecare specialty, optometrists conduct comprehensive eye examinations specifically designed to detect age-related risks that could result in eye diseases or vision loss. As millions of Baby Boomers enter their golden years, the field of geriatric optometry is experiencing an unprecedented demand. According to the U.S. Census Bureau, more than 20 percent of U.S. residents are projected to be 65 and older by 2030, up from 13 percent in 2010. VMAIL Weekend reached out to several optometrists to get their perspectives on the rewards, challenges and requirements associated with incorporating geriatric vision care into a practice.
HAMBURG, Germany—Global eyewear provider Fielmann Group announced preliminary consolidated sales of €1.25 billion for the first half of 2026, marking a 2 percent year-over-year increase from €1.23 billion for the first half of 2025. This growth was supported by a modest expansion in Fielmann Germany and a significant acceleration in international sales, which jumped from 1 percent growth in Q1 to 6 percent in Q2 on a year-over-year basis. In constant currency, the company's international markets also posted a 6 percent growth rate in Q2, led by Spain and Poland with constant currency increases of 10 percent and 7 percent, respectively, compared with the same quarter last year.
VAUGHAN, Ontario and MENLO PARK, Calif.—Global eye health company Bausch + Lomb Corporation (NYSE/TSX: BLCO) has announced the creation of Orphia, a brand-agnostic, AI-powered digital health platform designed to support eyecare providers and improve patient education. Orphia will serve all eyecare providers, regardless of the products, devices or treatments they choose to use, and it will operate under Digital Health Services, a newly-created platform at Bausch + Lomb, the company said in the announcement.
IRVINE, Calif.—Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a biopharmaceutical company focused on therapeutic eyecare, has announced the acquisition of iRenix Medical, Inc., a privately held, clinical-stage ophthalmic biopharmaceutical company and developer of IRX-101, an investigational ocular antiseptic with the potential to reduce post-procedural pain and corneal toxicity in patients receiving intravitreal therapy. The companies disclosed that the financial transaction included an upfront consideration of approximately $75 million, consisting of $37.5 million in cash and $37.5 million in Tarsus common stock, with potential approval and commercial milestone payments of up to $490 million.
VANCOUVER, B.C.—Kits Eyecare Ltd. (TSX: KITS), a leading vertically integrated eyecare provider based in Canada, has announced selected preliminary unaudited results for its second quarter ended June 30, 2026. In making the announcement, the company reported a preliminary total unaudited revenue of approximately $58.2 million, an increase of 17.3 percent year-over-year compared with the same period in 2025. Kits advised it intends to report its full second quarter 2026 results in early August with details for the second quarter conference call to be disclosed in the coming weeks.
MIAMI—Innovative Eyewear, Inc. (NASDAQ: LUCYW), the developer and manufacturer of smart eyewear under the Lucyd, Lucyd Armor, Reebok, Nautica, and Eddie Bauer brands, announced it has entered into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase an aggregate of 2,200,544 shares of the company's common stock originally issued by the company on April 14, 2025, and June 24, 2025, each having an original exercise price of $2.60 per share, at a reduced exercise price of $1.35 per share.
Editor’s note: This is a developing news story. Please check back soon for updates. The FDA granted 510(k) clearance for iPredict-DR, an AI-powered screening software designed to detect more than mild diabetic retinopathy in adults with diabetes, according to a press release from iHealthScreen. The clearance was supported by data from a clinical validation trial that looked at “diagnostic performance, safety and usability.” The software uses AI to examine color retinal fundus images taken with an iCare DRSplus camera, which is designed to be operable by minimally skilled health care workers.
Editor’s note: This is a developing news story. Please check back soon for updates. More than 2.5 million bottles of steroid eye drops aimed at relieving inflammation have been recalled, according to the FDA. Lupin Pharmaceuticals is recalling 2,530,182 bottles of prednisolone acetate ophthalmic solution 1%, including 5 mL, 10 mL and 15 mL bottles. The affected lots have expiration dates ranging from July 31, 2026, to March 31, 2028. The stated reason for the recall is “presence of foreign substance.” The recall, issued on June 4, is class II, meaning the products could cause
Amniotic membrane has been in clinical use in ophthalmology for more than half a century. The histological nature of the membrane has been used for various eye surface diseases, and indications have expanded. Amniotic membrane (AM) is the innermost layer of the placenta and consists of a thick basement membrane and an avascular stromal matrix. Since its first ophthalmic use in the 1940s and its reintroduction by Tseng and colleagues in the 1990s, amniotic membrane transplantation (AMT) has become an important tool in ocular surface reconstruction. AM is composed of five layers: epithelial
Amniotic membrane has been in clinical use in ophthalmology for more than half a century. The histological nature of the membrane has been used for various eye surface diseases, and indications have expanded. Amniotic membrane (AM) is the innermost layer of the placenta and consists of a thick basement membrane and an avascular stromal matrix. Since its first ophthalmic use in the 1940s and its reintroduction by Tseng and colleagues in the 1990s, amniotic membrane transplantation (AMT) has become an important tool in ocular surface reconstruction. AM is composed of five layers: epithelial
From talent development and intergenerational dialogue to welfare and inclusive leadership, ANFAO vice president Sabrina Paulon discusses the initiatives supporting the growth of both companies and people. Paulon said, “Over the past few years, we have worked to support companies in a process of cultural growth by promoting initiatives focused on inclusion, inclusive language and the value of people.”
Gathering and analyzing patient feedback has moved beyond a “nice to have" and is now an essential tool for the growth and success of an optometry practice. By actively collecting and evaluating this input, optometrists can reap the benefits of enhanced patient loyalty and streamlined office operations, while maintaining clinical excellence. Patient feedback provides critical insights into several key areas, starting with clinical quality and safety, where it helps identify deficiencies in exams, treatment plan communication, and patients’ understanding of vision conditions.
For many practice owners, operational demands usually take precedence and branding seldom tops their daily to-do list. Acknowledging that an image change is needed can often be the first step taken when it comes to rebranding an optometry practice. But this leads to a critical question: how do you identify the perfect time to execute a rebrand? A successful rebranding process shifts the focus away from a mere name change toward a more holistic evolution of market positioning, practice culture, and most importantly, the overall patient experience. A clear vision for the practice’s new identity is essential to any rebranding effort.
Safety in an optometrist's office is essential to protecting both patients and staff while creating a professional, efficient and trusted healthcare environment. Establishing strong health and safety practices helps ensure everyone who enters the practice can feel confident that their well-being is a top priority. Developing a comprehensive safety program should begin with identifying potential hazards and implementing clear protocols to reduce risk, according to Susan Primo, OD, the director of optometry and vision rehabilitation services and program coordinator of the optometric residency at the Emory Eye Center.
ROCHESTER, N.Y.—CooperVision, a division of CooperCompanies (Nasdaq:COO) and a leading manufacturer of contact lenses, has announced the promotion of Jennifer Palombi, OD, FAAO, to director of professional affairs, Americas, and Felicia Timmermann, OD, MS, FAAO, to senior advisor, myopia management, U.S. Both appointments are effective immediately and reflect what the company noted is a “continued investment in its professional affairs organization and…focus on providing practitioners with innovative products, clinical education, insights and resources to meet the needs of their patients.”
SIOUX FALLS, S.D.—Balance Ophthalmics, a medical device company advancing non-pharmacological, non-surgical treatment options for glaucoma, has announced the appointment of Norbert Lowe as chief commercial officer, effective immediately. In this new role, Lowe will lead the company’s commercial strategy and execution as it prepares to expand awareness and adoption of the FSYX (pronounced “physics”) Ocular Pressure Adjusting Pump (OPAP). Balance said this appointment comes at a pivotal time, following the FDA 510(k) clearance of the wireless-enabled next-generation FSYX system in May 2026 and ahead of anticipated broader commercialization.
TREVISO, Italy and SAN CLEMENTE, Calif.—Rudy Project, an Italian leader in the design and manufacturing of high-performance sports helmets and eyewear, has acquired ownership of Rudy Project North America L.P., its exclusive North American distributor, as of February 2026. Rudy Project will now operate directly in the U.S. market, the company said. This strategic operation also includes the Caribbean region. Alongside this acquisition, Rudy Project appointed Jaclyn Mayer as general manager of Rudy Project North America, effective May 1, 2026. Mayer joins the company following several leadership roles at Canyon Bicycles USA, where she most recently led retail, service and customer experience initiatives across North America.
Alcon and RxSight announced a nonexclusive collaboration to develop a light-adjustable presbyopia-correcting IOL, according to a press release. “This collaboration will enable surgeons to fine-tune visual outcomes for their cataract patients who choose a PCIOL, which is not an available option today,” Ron Kurtz, MD, president and CEO of RxSight, told Healio. The collaboration aims to combine RxSight’s postoperative light-adjustable technology with Alcon’s presbyopia-correcting optical designs to create the novel IOL technology. Alcon will pay RxSight $60 million upfront to begin development,
The AMA has adopted a resolution supporting insurance reimbursement for myopia treatment, saying the condition is a significant public health concern and should be formally classified as “a disease” by CMS. This comes as the FDA approves an increasing array of options for reducing myopia and slowing its progression, including spectacle and contact lenses. The global prevalence of myopia has been forecasted to reach 50% by 2050. The resolution, adopted by AMA’s House of Delegates in June, says that AMA supports “efforts to ensure comprehensive insurance coverage and reimbursement for
Most Canadians know to apply sunscreen before heading outdoors, but many don’t realize another part of the body is just as vulnerable to the sun: their eyes. As Canadians spend more time outside this summer, the Canadian Ophthalmological Society (COS) is reminding the public that prolonged exposure to ultraviolet (UV) radiation can damage the eyes, with effects that build over time.
ST. LOUIS—Last week, PERC announced the launch of PERC+, a new membership offering that the group said is designed to help independent eyecare practices strengthen their businesses through enhanced purchasing value, strategic partnerships, peer collaboration and deeper engagement with the alliance. General manager Jason Lake, OD, has led PERC to expand its focus beyond purchasing value, the group said, investing additionally in peer-to-peer collaboration, developing strategic partnerships and creating resources to help members make more informed decisions. PERC+ will build upon this growth by creating new opportunities for practices to realize greater value from the purchasing decisions they are already making, the announcement noted.
LONDON—The International Agency for the Prevention of Blindness (IAPB) has announced the launch of its 2026 World Sight Day campaign, encouraging the eyecare sector to unite behind the Agency’s global movement to #LoveYourEyes. This year’s campaign, which aligns with World Sight Day on October 8, positions stories, lived experiences and community action at the heart of the movement, according to the announcement from IAPB.
RANCHO CORDOVA, Calif.—VSP Ventures, a VSP Vision company that provides practice transition options for private practice doctors of optometry, today announced that six new optometric practices across California have joined the organization. Now including more than 100 practices across the country, the six newest practices within VSP Ventures include Buena Vista Eyecare Optometry in San Jose, San Gabriel Family Optometry in San Gabriel, El Dorado Hills Optometric Center in El Dorado Hills, Borel Eye Doctors of Optometry in San Mateo, Visionmax Optometry in Porter Ranch and 2 See Optometry in Glendale.
ALISO VIEJO, Calif.—RxSight, Inc. (NASDAQ: RXST), an ophthalmic medical device company focused on improving vision after cataract surgery, has announced select preliminary financial results for the second quarter of 2026 and provided updates to its standalone product pipeline. This follows the announcement on July 6 about the company’s strategic collaboration with Alcon to develop and commercialize light-adjustable presbyopia-correcting intraocular lenses. Total company revenue for the second quarter of 2026 is expected to be approximately $32 million to $34 million, which includes $5 million to $7 million in revenue recognized from the RxSight Alcon strategic collaboration, with the specific amount expected to be reported in August with the company’s financial results for the second quarter of 2026.
SAINT LUCIA—RestoringVision announced it has signed a memorandum of understanding (MoU) with the government of Saint Lucia to expand access to essential vision care services, marking a significant step toward improving eye health and quality of life across the island. The agreement, signed on June 18, 2026, supports a Prime Ministerial Vision Initiative that will integrate presbyopia screening and the distribution of near-vision eyeglasses into Saint Lucia’s public health system, the announcement said. Through the partnership, RestoringVision said it will provide 50,000 pairs of eyeglasses.
SAN DIEGO—LENZ Therapeutics, Inc. (Nasdaq: LENZ), a pharmaceutical company focused on the commercialization of VIZZ (aceclidine ophthalmic solution) 1.44%, an aceclidine-based eye drop for the treatment of presbyopia, has announced that VIZZ is now available through a new telehealth platform, providing the convenience of an integrated online evaluation by independent licensed eyecare providers, e-pharmacy prescription fulfillment and home delivery. By visiting the integrated telehealth platform, patients can fill out and submit an online medical history form, allowing an independent network of licensed ECPs to connect with patients and evaluate their eligibility for telehealth services. Prescriptions will be automatically routed and fulfilled by LENZ’s e-pharmacy partner, the announcement said.
NEWARK, N.J.—Jobson Research has issued the 2026 iteration of its Census ProCount, a database of approximately 38,000 optical locations in the U.S. The database features independents and chains with up to 50 locations that are open and operating in 2026. The Census data contains the practice/company name, address, phone, county, website, estimated annual retail sales, square footage, newly established locations and practice emphasis (optometry, ophthalmology or sunglasses). Census ProCount can be used for sales force analysis, prospecting lists, penetration analysis, sales territory organization and more.
An 82-year-old woman presented with a 20-year history of a soft, nontender right medial canthal mass below the medial canthal tendon (A). Complete compressibility with rapid spontaneous refilling, absence of epiphora, and patent lacrimal irrigation suggested a vascular lesion rather than lacrimal sac pathology. Computed tomography demonstrated a 12 × 16 mm superficial varicose dilatation of the angular vein (red arrow, B). Surgical excision with proximal and distal ligation was performed for cosmetic reasons (C).
In previous articles, I introduced retinal reserve as a framework for understanding the retina’s ability to maintain function despite underlying stress and dysfunction. If functional decline often precedes visible structural damage, an important clinical question follows: How do we measure retinal reserve before irreversible loss occurs? While OCT remains foundational, I believe the next frontier of proactive retinal care will combine functional testing with targeted systemic biomarkers (Owsley et al.). Together, these tools may help identify retinal stress before structural disease
Editor’s note: This is a developing news story. Please check back soon for updates. The FDA granted regenerative medicine advanced therapy designation to EO2002 for the treatment of corneal edema secondary to corneal endothelial dysfunction, according to a press release from Emmecell. The allogeneic cultured human corneal endothelial cell therapy uses the company’s Magnetic Cell Delivery platform to restore corneal endothelial function by improving the localization and retention of therapeutic cells, the release said. This helps restore function without interventions such as endothelial
Safilo Group announced the closing of the acquisition of SPY+ and Serengeti from Bollé Brands, following the signing of a Share and Asset Purchase Agreement on May 11, 2026, and the fulfilment of all customary closing conditions. The transaction covers selected SPY+ and Serengeti assets in Europe and 100 percent of the shares of two dedicated legal entities operating in the United States and Canada.
Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a society of cornea, cataract and refractive surgery specialists, here to discuss some of the latest hot topics in ophthalmology. We spend so much time talking about our journey into ophthalmology — how to build a practice, run it and make it grow — but we rarely discuss the other end of our journey into retirement and beyond. From the experience of two esteemed colleagues, Cynthia Matossian, MD, FACS, and Denise M. Visco, MD, MBA, you will learn that retirement, far from being the end of the story, can be the start of a new
Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a society of cornea, cataract and refractive surgery specialists, here to discuss some of the latest hot topics in ophthalmology. We spend so much time talking about our journey into ophthalmology — how to build a practice, run it and make it grow — but we rarely discuss the other end of our journey into retirement and beyond. From the experience of two esteemed colleagues, Cynthia Matossian, MD, FACS, and Denise M. Visco, MD, MBA, you will learn that retirement, far from being the end of the story, can be the start of a new
MIAMI—Innovative Eyewear, Inc. (NASDAQ: LUCY; LUCYW), the developer and manufacturer of smart eyewear under the Lucyd, Lucyd Armor, Reebok, Eddie Bauer and Nautica brands, has announced what it’s calling “a significant new retail launch” with FYihealth group, operators of the FYidoctors optical chain and retail brands including Visique, solis optics and BonLook. The partnership centers on the 2026 rollout of Lucyd Armor smart safety eyewear in 345 FYidoctors and Visique clinic locations, with initial product placement expected to commence in the third quarter of 2026, the company advised.
ALISO VIEJO, Calif.—Alcon (SIX/NYSE: ALC), a global leader in eyecare, and RxSight, Inc. (NASDAQ: RXST), an ophthalmic medical device company focused on providing high-quality customized vision to patients following cataract surgery, have announced a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting intraocular lenses (PCIOLs). As part of the agreement, RxSight will receive a $60 million upfront payment to begin development and could receive up to an additional $140 million in payments as development and regulatory milestones are met, the announcement stated.
BARCELONA and SCOTTSDALE, Ariz.—aura-ai, a leading optical technology portfolio developed by Horizons Optical, has announced the appointment of industry veteran Randy Dannewitz as its new chief commercial officer, a move the company said brings one of the optical industry's most accomplished commercial and product development leaders to its executive team. In his new role, Dannewitz will lead aura-ai's commercial strategy, sales, marketing and business development initiatives as the company continues to expand its presence among independent eyecare professionals and optical laboratories.
MIAMI, Fla.—Innovative Eyewear, Inc. (NASDAQ: LUCYW), the developer and manufacturer of smart eyewear under the Lucyd, Lucyd Armor, Reebok, Nautica, and Eddie Bauer brands, has reported preliminary, unaudited net sales for the second quarter ended June 30, 2026, demonstrating an increase of approximately 71 percent year-over-year to $0.99 million. Growth continued to be led by the Lucyd Armor smart safety eyewear line, the company stated, with a sustained level of demand across the direct-to-consumer, online marketplace, and wholesale channels.
WESTPORT, Conn.—Look Optic, a modern eyewear brand known for its over-the-counter progressive reading glasses, has announced the closing of a Series B financing round. Connecticut Innovations, which has backed Look Optic since its Series A funding round, led the Series B round and increased its position alongside Alex Rodriguez and Billie Jean King, who recently joined as both investors and advisors, the announcement said. This latest round of financing will be used to expand the brand into men’s eyewear and sun products, the company said, as well as to accelerate channel expansion into retail. Its first brick-and-mortar store is scheduled to open in NYC on November 1.
Infections associated with laser vision correction procedures remain a rare but potentially devastating occurrence. Precise rates of infection are uncertain due to underreporting and incomplete reporting. Estimates suggest an approximate incidence rate of one in 5,000 LASIK procedures and one in 1,000 surface ablation procedures, higher in part due to breach of the corneal epithelial barrier and use of a therapeutic contact lens. Around 2000, a shift in the organisms recovered in laser vision correction (LVC)-associated infections was observed from common pathogens such as staphylococci,
FRONHAUSEN, Germany—Schneider Optical Machines welcomed more than 250 industry professionals from 50 countries to DigiCON 2026, its customer and innovation event held in July at the company's facilities in Fronhausen and Marburg, Germany, the company said in an announcement.
Two methods of cataract surgery — phacoemulsification and manual small-incision cataract surgery — can lead to “acute detrimental effects on the ocular surface,” including dry eye and increased inflammation, according to a study. “Cataract surgery is ... responsible for transiently inducing or exacerbating dry eye, and several studies have shown that uncomplicated phacoemulsification can increase dry eye symptoms,” Geeta Behera, of the department of ophthalmology at Jawaharlal Institute of Post-Graduate Medical Education and Research, India, and colleagues
Click here to read the Healio Exclusive, “Ophthalmic innovation: Growing a product from idea to market.” Practicing ophthalmologists have an amazing legacy of catalyzing innovation to enhance our ability to retain, restore and enhance our patients’ vision. Notable examples include Sir Harold Ridley and the intraocular lens; Charles Kelman, MD, and phacoemulsification; Richard Hill, MD, and MIGS; Steve Trokel, MD, and excimer laser corneal refractive surgery; Alan Scott, MD, and Botox; Gerhard Meyer-Schwickerath, MD, and retinal photocoagulation; and Philip Rosenfeld, MD, PhD, and intravitreal
The FDA favorably reviewed plans for a phase 3 trial of urcosimod, which is being investigated for the treatment of neuropathic corneal pain, according to a press release from Okyo Pharma. The feedback came during a meeting between Okyo Pharma and the FDA, paving the way for a pivotal trial in a disease that currently has no specifically approved treatments. “Neuropathic corneal pain remains one of the most challenging and underserved conditions in eye care, with patients often living with persistent pain,” Robert J. Dempsey, CEO of Okyo Pharma, told Healio. The trial, called
GIGI Studios is celebrating its 10th anniversary in 2026, marking a decade of growth for the Barcelona-based eyewear brand. Founded on a family heritage of more than 60 years in the eyewear sector, the brand has built its identity around contemporary design, craftsmanship and a fashion-led creative direction.
A 76-year-old man presented with a 3-week history of binocular vertical diplopia. He denied change in vision, pain with eye movements, headache, scalp tenderness, jaw claudication, constitutional symptoms, dysarthria, extremity numbness or tingling, facial droop, and prior similar episodes. Ocular history was notable for dry age-related macular degeneration in the right eye, neovascular AMD in the left eye and cataract extraction bilaterally. He had previously received intravitreal anti-VEGF injections at an outside institution but had been lost to follow-up for several years. Medical history
Geriatric optometry, which focuses on the unique eye health and vision requirements of older adults, is having a moment in the vision care sector. Within this eyecare specialty, optometrists conduct comprehensive eye examinations specifically designed to detect age-related risks that could result in eye diseases or vision loss. As millions of Baby Boomers enter their golden years, the field of geriatric optometry is experiencing an unprecedented demand. According to the U.S. Census Bureau, more than 20 percent of U.S. residents are projected to be 65 and older by 2030, up from 13 percent in 2010. VMAIL Weekend reached out to several optometrists to get their perspectives on the rewards, challenges and requirements associated with incorporating geriatric vision care into a practice.
HAMBURG, Germany—Global eyewear provider Fielmann Group announced preliminary consolidated sales of €1.25 billion for the first half of 2026, marking a 2 percent year-over-year increase from €1.23 billion for the first half of 2025. This growth was supported by a modest expansion in Fielmann Germany and a significant acceleration in international sales, which jumped from 1 percent growth in Q1 to 6 percent in Q2 on a year-over-year basis. In constant currency, the company's international markets also posted a 6 percent growth rate in Q2, led by Spain and Poland with constant currency increases of 10 percent and 7 percent, respectively, compared with the same quarter last year.
VAUGHAN, Ontario and MENLO PARK, Calif.—Global eye health company Bausch + Lomb Corporation (NYSE/TSX: BLCO) has announced the creation of Orphia, a brand-agnostic, AI-powered digital health platform designed to support eyecare providers and improve patient education. Orphia will serve all eyecare providers, regardless of the products, devices or treatments they choose to use, and it will operate under Digital Health Services, a newly-created platform at Bausch + Lomb, the company said in the announcement.
IRVINE, Calif.—Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a biopharmaceutical company focused on therapeutic eyecare, has announced the acquisition of iRenix Medical, Inc., a privately held, clinical-stage ophthalmic biopharmaceutical company and developer of IRX-101, an investigational ocular antiseptic with the potential to reduce post-procedural pain and corneal toxicity in patients receiving intravitreal therapy. The companies disclosed that the financial transaction included an upfront consideration of approximately $75 million, consisting of $37.5 million in cash and $37.5 million in Tarsus common stock, with potential approval and commercial milestone payments of up to $490 million.
VANCOUVER, B.C.—Kits Eyecare Ltd. (TSX: KITS), a leading vertically integrated eyecare provider based in Canada, has announced selected preliminary unaudited results for its second quarter ended June 30, 2026. In making the announcement, the company reported a preliminary total unaudited revenue of approximately $58.2 million, an increase of 17.3 percent year-over-year compared with the same period in 2025. Kits advised it intends to report its full second quarter 2026 results in early August with details for the second quarter conference call to be disclosed in the coming weeks.
MIAMI—Innovative Eyewear, Inc. (NASDAQ: LUCYW), the developer and manufacturer of smart eyewear under the Lucyd, Lucyd Armor, Reebok, Nautica, and Eddie Bauer brands, announced it has entered into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase an aggregate of 2,200,544 shares of the company's common stock originally issued by the company on April 14, 2025, and June 24, 2025, each having an original exercise price of $2.60 per share, at a reduced exercise price of $1.35 per share.
Editor’s note: This is a developing news story. Please check back soon for updates. The FDA granted 510(k) clearance for iPredict-DR, an AI-powered screening software designed to detect more than mild diabetic retinopathy in adults with diabetes, according to a press release from iHealthScreen. The clearance was supported by data from a clinical validation trial that looked at “diagnostic performance, safety and usability.” The software uses AI to examine color retinal fundus images taken with an iCare DRSplus camera, which is designed to be operable by minimally skilled health care workers.
Editor’s note: This is a developing news story. Please check back soon for updates. More than 2.5 million bottles of steroid eye drops aimed at relieving inflammation have been recalled, according to the FDA. Lupin Pharmaceuticals is recalling 2,530,182 bottles of prednisolone acetate ophthalmic solution 1%, including 5 mL, 10 mL and 15 mL bottles. The affected lots have expiration dates ranging from July 31, 2026, to March 31, 2028. The stated reason for the recall is “presence of foreign substance.” The recall, issued on June 4, is class II, meaning the products could cause
Amniotic membrane has been in clinical use in ophthalmology for more than half a century. The histological nature of the membrane has been used for various eye surface diseases, and indications have expanded. Amniotic membrane (AM) is the innermost layer of the placenta and consists of a thick basement membrane and an avascular stromal matrix. Since its first ophthalmic use in the 1940s and its reintroduction by Tseng and colleagues in the 1990s, amniotic membrane transplantation (AMT) has become an important tool in ocular surface reconstruction. AM is composed of five layers: epithelial
Amniotic membrane has been in clinical use in ophthalmology for more than half a century. The histological nature of the membrane has been used for various eye surface diseases, and indications have expanded. Amniotic membrane (AM) is the innermost layer of the placenta and consists of a thick basement membrane and an avascular stromal matrix. Since its first ophthalmic use in the 1940s and its reintroduction by Tseng and colleagues in the 1990s, amniotic membrane transplantation (AMT) has become an important tool in ocular surface reconstruction. AM is composed of five layers: epithelial
From talent development and intergenerational dialogue to welfare and inclusive leadership, ANFAO vice president Sabrina Paulon discusses the initiatives supporting the growth of both companies and people. Paulon said, “Over the past few years, we have worked to support companies in a process of cultural growth by promoting initiatives focused on inclusion, inclusive language and the value of people.”
Gathering and analyzing patient feedback has moved beyond a “nice to have" and is now an essential tool for the growth and success of an optometry practice. By actively collecting and evaluating this input, optometrists can reap the benefits of enhanced patient loyalty and streamlined office operations, while maintaining clinical excellence. Patient feedback provides critical insights into several key areas, starting with clinical quality and safety, where it helps identify deficiencies in exams, treatment plan communication, and patients’ understanding of vision conditions.
For many practice owners, operational demands usually take precedence and branding seldom tops their daily to-do list. Acknowledging that an image change is needed can often be the first step taken when it comes to rebranding an optometry practice. But this leads to a critical question: how do you identify the perfect time to execute a rebrand? A successful rebranding process shifts the focus away from a mere name change toward a more holistic evolution of market positioning, practice culture, and most importantly, the overall patient experience. A clear vision for the practice’s new identity is essential to any rebranding effort.
Safety in an optometrist's office is essential to protecting both patients and staff while creating a professional, efficient and trusted healthcare environment. Establishing strong health and safety practices helps ensure everyone who enters the practice can feel confident that their well-being is a top priority. Developing a comprehensive safety program should begin with identifying potential hazards and implementing clear protocols to reduce risk, according to Susan Primo, OD, the director of optometry and vision rehabilitation services and program coordinator of the optometric residency at the Emory Eye Center.
ROCHESTER, N.Y.—CooperVision, a division of CooperCompanies (Nasdaq:COO) and a leading manufacturer of contact lenses, has announced the promotion of Jennifer Palombi, OD, FAAO, to director of professional affairs, Americas, and Felicia Timmermann, OD, MS, FAAO, to senior advisor, myopia management, U.S. Both appointments are effective immediately and reflect what the company noted is a “continued investment in its professional affairs organization and…focus on providing practitioners with innovative products, clinical education, insights and resources to meet the needs of their patients.”
SIOUX FALLS, S.D.—Balance Ophthalmics, a medical device company advancing non-pharmacological, non-surgical treatment options for glaucoma, has announced the appointment of Norbert Lowe as chief commercial officer, effective immediately. In this new role, Lowe will lead the company’s commercial strategy and execution as it prepares to expand awareness and adoption of the FSYX (pronounced “physics”) Ocular Pressure Adjusting Pump (OPAP). Balance said this appointment comes at a pivotal time, following the FDA 510(k) clearance of the wireless-enabled next-generation FSYX system in May 2026 and ahead of anticipated broader commercialization.
TREVISO, Italy and SAN CLEMENTE, Calif.—Rudy Project, an Italian leader in the design and manufacturing of high-performance sports helmets and eyewear, has acquired ownership of Rudy Project North America L.P., its exclusive North American distributor, as of February 2026. Rudy Project will now operate directly in the U.S. market, the company said. This strategic operation also includes the Caribbean region. Alongside this acquisition, Rudy Project appointed Jaclyn Mayer as general manager of Rudy Project North America, effective May 1, 2026. Mayer joins the company following several leadership roles at Canyon Bicycles USA, where she most recently led retail, service and customer experience initiatives across North America.
Alcon and RxSight announced a nonexclusive collaboration to develop a light-adjustable presbyopia-correcting IOL, according to a press release. “This collaboration will enable surgeons to fine-tune visual outcomes for their cataract patients who choose a PCIOL, which is not an available option today,” Ron Kurtz, MD, president and CEO of RxSight, told Healio. The collaboration aims to combine RxSight’s postoperative light-adjustable technology with Alcon’s presbyopia-correcting optical designs to create the novel IOL technology. Alcon will pay RxSight $60 million upfront to begin development,
The AMA has adopted a resolution supporting insurance reimbursement for myopia treatment, saying the condition is a significant public health concern and should be formally classified as “a disease” by CMS. This comes as the FDA approves an increasing array of options for reducing myopia and slowing its progression, including spectacle and contact lenses. The global prevalence of myopia has been forecasted to reach 50% by 2050. The resolution, adopted by AMA’s House of Delegates in June, says that AMA supports “efforts to ensure comprehensive insurance coverage and reimbursement for
Most Canadians know to apply sunscreen before heading outdoors, but many don’t realize another part of the body is just as vulnerable to the sun: their eyes. As Canadians spend more time outside this summer, the Canadian Ophthalmological Society (COS) is reminding the public that prolonged exposure to ultraviolet (UV) radiation can damage the eyes, with effects that build over time.
ST. LOUIS—Last week, PERC announced the launch of PERC+, a new membership offering that the group said is designed to help independent eyecare practices strengthen their businesses through enhanced purchasing value, strategic partnerships, peer collaboration and deeper engagement with the alliance. General manager Jason Lake, OD, has led PERC to expand its focus beyond purchasing value, the group said, investing additionally in peer-to-peer collaboration, developing strategic partnerships and creating resources to help members make more informed decisions. PERC+ will build upon this growth by creating new opportunities for practices to realize greater value from the purchasing decisions they are already making, the announcement noted.
LONDON—The International Agency for the Prevention of Blindness (IAPB) has announced the launch of its 2026 World Sight Day campaign, encouraging the eyecare sector to unite behind the Agency’s global movement to #LoveYourEyes. This year’s campaign, which aligns with World Sight Day on October 8, positions stories, lived experiences and community action at the heart of the movement, according to the announcement from IAPB.
RANCHO CORDOVA, Calif.—VSP Ventures, a VSP Vision company that provides practice transition options for private practice doctors of optometry, today announced that six new optometric practices across California have joined the organization. Now including more than 100 practices across the country, the six newest practices within VSP Ventures include Buena Vista Eyecare Optometry in San Jose, San Gabriel Family Optometry in San Gabriel, El Dorado Hills Optometric Center in El Dorado Hills, Borel Eye Doctors of Optometry in San Mateo, Visionmax Optometry in Porter Ranch and 2 See Optometry in Glendale.
ALISO VIEJO, Calif.—RxSight, Inc. (NASDAQ: RXST), an ophthalmic medical device company focused on improving vision after cataract surgery, has announced select preliminary financial results for the second quarter of 2026 and provided updates to its standalone product pipeline. This follows the announcement on July 6 about the company’s strategic collaboration with Alcon to develop and commercialize light-adjustable presbyopia-correcting intraocular lenses. Total company revenue for the second quarter of 2026 is expected to be approximately $32 million to $34 million, which includes $5 million to $7 million in revenue recognized from the RxSight Alcon strategic collaboration, with the specific amount expected to be reported in August with the company’s financial results for the second quarter of 2026.
SAINT LUCIA—RestoringVision announced it has signed a memorandum of understanding (MoU) with the government of Saint Lucia to expand access to essential vision care services, marking a significant step toward improving eye health and quality of life across the island. The agreement, signed on June 18, 2026, supports a Prime Ministerial Vision Initiative that will integrate presbyopia screening and the distribution of near-vision eyeglasses into Saint Lucia’s public health system, the announcement said. Through the partnership, RestoringVision said it will provide 50,000 pairs of eyeglasses.
SAN DIEGO—LENZ Therapeutics, Inc. (Nasdaq: LENZ), a pharmaceutical company focused on the commercialization of VIZZ (aceclidine ophthalmic solution) 1.44%, an aceclidine-based eye drop for the treatment of presbyopia, has announced that VIZZ is now available through a new telehealth platform, providing the convenience of an integrated online evaluation by independent licensed eyecare providers, e-pharmacy prescription fulfillment and home delivery. By visiting the integrated telehealth platform, patients can fill out and submit an online medical history form, allowing an independent network of licensed ECPs to connect with patients and evaluate their eligibility for telehealth services. Prescriptions will be automatically routed and fulfilled by LENZ’s e-pharmacy partner, the announcement said.
NEWARK, N.J.—Jobson Research has issued the 2026 iteration of its Census ProCount, a database of approximately 38,000 optical locations in the U.S. The database features independents and chains with up to 50 locations that are open and operating in 2026. The Census data contains the practice/company name, address, phone, county, website, estimated annual retail sales, square footage, newly established locations and practice emphasis (optometry, ophthalmology or sunglasses). Census ProCount can be used for sales force analysis, prospecting lists, penetration analysis, sales territory organization and more.
An 82-year-old woman presented with a 20-year history of a soft, nontender right medial canthal mass below the medial canthal tendon (A). Complete compressibility with rapid spontaneous refilling, absence of epiphora, and patent lacrimal irrigation suggested a vascular lesion rather than lacrimal sac pathology. Computed tomography demonstrated a 12 × 16 mm superficial varicose dilatation of the angular vein (red arrow, B). Surgical excision with proximal and distal ligation was performed for cosmetic reasons (C).
In previous articles, I introduced retinal reserve as a framework for understanding the retina’s ability to maintain function despite underlying stress and dysfunction. If functional decline often precedes visible structural damage, an important clinical question follows: How do we measure retinal reserve before irreversible loss occurs? While OCT remains foundational, I believe the next frontier of proactive retinal care will combine functional testing with targeted systemic biomarkers (Owsley et al.). Together, these tools may help identify retinal stress before structural disease
Editor’s note: This is a developing news story. Please check back soon for updates. The FDA granted regenerative medicine advanced therapy designation to EO2002 for the treatment of corneal edema secondary to corneal endothelial dysfunction, according to a press release from Emmecell. The allogeneic cultured human corneal endothelial cell therapy uses the company’s Magnetic Cell Delivery platform to restore corneal endothelial function by improving the localization and retention of therapeutic cells, the release said. This helps restore function without interventions such as endothelial
Safilo Group announced the closing of the acquisition of SPY+ and Serengeti from Bollé Brands, following the signing of a Share and Asset Purchase Agreement on May 11, 2026, and the fulfilment of all customary closing conditions. The transaction covers selected SPY+ and Serengeti assets in Europe and 100 percent of the shares of two dedicated legal entities operating in the United States and Canada.
Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a society of cornea, cataract and refractive surgery specialists, here to discuss some of the latest hot topics in ophthalmology. We spend so much time talking about our journey into ophthalmology — how to build a practice, run it and make it grow — but we rarely discuss the other end of our journey into retirement and beyond. From the experience of two esteemed colleagues, Cynthia Matossian, MD, FACS, and Denise M. Visco, MD, MBA, you will learn that retirement, far from being the end of the story, can be the start of a new
Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a society of cornea, cataract and refractive surgery specialists, here to discuss some of the latest hot topics in ophthalmology. We spend so much time talking about our journey into ophthalmology — how to build a practice, run it and make it grow — but we rarely discuss the other end of our journey into retirement and beyond. From the experience of two esteemed colleagues, Cynthia Matossian, MD, FACS, and Denise M. Visco, MD, MBA, you will learn that retirement, far from being the end of the story, can be the start of a new
MIAMI—Innovative Eyewear, Inc. (NASDAQ: LUCY; LUCYW), the developer and manufacturer of smart eyewear under the Lucyd, Lucyd Armor, Reebok, Eddie Bauer and Nautica brands, has announced what it’s calling “a significant new retail launch” with FYihealth group, operators of the FYidoctors optical chain and retail brands including Visique, solis optics and BonLook. The partnership centers on the 2026 rollout of Lucyd Armor smart safety eyewear in 345 FYidoctors and Visique clinic locations, with initial product placement expected to commence in the third quarter of 2026, the company advised.
ALISO VIEJO, Calif.—Alcon (SIX/NYSE: ALC), a global leader in eyecare, and RxSight, Inc. (NASDAQ: RXST), an ophthalmic medical device company focused on providing high-quality customized vision to patients following cataract surgery, have announced a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting intraocular lenses (PCIOLs). As part of the agreement, RxSight will receive a $60 million upfront payment to begin development and could receive up to an additional $140 million in payments as development and regulatory milestones are met, the announcement stated.
BARCELONA and SCOTTSDALE, Ariz.—aura-ai, a leading optical technology portfolio developed by Horizons Optical, has announced the appointment of industry veteran Randy Dannewitz as its new chief commercial officer, a move the company said brings one of the optical industry's most accomplished commercial and product development leaders to its executive team. In his new role, Dannewitz will lead aura-ai's commercial strategy, sales, marketing and business development initiatives as the company continues to expand its presence among independent eyecare professionals and optical laboratories.
MIAMI, Fla.—Innovative Eyewear, Inc. (NASDAQ: LUCYW), the developer and manufacturer of smart eyewear under the Lucyd, Lucyd Armor, Reebok, Nautica, and Eddie Bauer brands, has reported preliminary, unaudited net sales for the second quarter ended June 30, 2026, demonstrating an increase of approximately 71 percent year-over-year to $0.99 million. Growth continued to be led by the Lucyd Armor smart safety eyewear line, the company stated, with a sustained level of demand across the direct-to-consumer, online marketplace, and wholesale channels.
WESTPORT, Conn.—Look Optic, a modern eyewear brand known for its over-the-counter progressive reading glasses, has announced the closing of a Series B financing round. Connecticut Innovations, which has backed Look Optic since its Series A funding round, led the Series B round and increased its position alongside Alex Rodriguez and Billie Jean King, who recently joined as both investors and advisors, the announcement said. This latest round of financing will be used to expand the brand into men’s eyewear and sun products, the company said, as well as to accelerate channel expansion into retail. Its first brick-and-mortar store is scheduled to open in NYC on November 1.
Infections associated with laser vision correction procedures remain a rare but potentially devastating occurrence. Precise rates of infection are uncertain due to underreporting and incomplete reporting. Estimates suggest an approximate incidence rate of one in 5,000 LASIK procedures and one in 1,000 surface ablation procedures, higher in part due to breach of the corneal epithelial barrier and use of a therapeutic contact lens. Around 2000, a shift in the organisms recovered in laser vision correction (LVC)-associated infections was observed from common pathogens such as staphylococci,
FRONHAUSEN, Germany—Schneider Optical Machines welcomed more than 250 industry professionals from 50 countries to DigiCON 2026, its customer and innovation event held in July at the company's facilities in Fronhausen and Marburg, Germany, the company said in an announcement.
Two methods of cataract surgery — phacoemulsification and manual small-incision cataract surgery — can lead to “acute detrimental effects on the ocular surface,” including dry eye and increased inflammation, according to a study. “Cataract surgery is ... responsible for transiently inducing or exacerbating dry eye, and several studies have shown that uncomplicated phacoemulsification can increase dry eye symptoms,” Geeta Behera, of the department of ophthalmology at Jawaharlal Institute of Post-Graduate Medical Education and Research, India, and colleagues
Click here to read the Healio Exclusive, “Ophthalmic innovation: Growing a product from idea to market.” Practicing ophthalmologists have an amazing legacy of catalyzing innovation to enhance our ability to retain, restore and enhance our patients’ vision. Notable examples include Sir Harold Ridley and the intraocular lens; Charles Kelman, MD, and phacoemulsification; Richard Hill, MD, and MIGS; Steve Trokel, MD, and excimer laser corneal refractive surgery; Alan Scott, MD, and Botox; Gerhard Meyer-Schwickerath, MD, and retinal photocoagulation; and Philip Rosenfeld, MD, PhD, and intravitreal
B-Seen aggregates headlines from leading eye care publications. All content belongs to its respective publishers. Want your publication featured or removed? Contact us.
